Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
about
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesMolecular Imaging of Biomarkers in Breast CancerEstrogen receptor degradation: a CUE for endocrine resistance?Progesterone receptor modulates ERα action in breast cancer.Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical DilemmasPrognostic significance of deregulated dicer expression in breast cancerMembrane progesterone receptor alpha as a potential prognostic biomarker for breast cancer survival: a retrospective studyDeciphering the divergent roles of progestogens in breast cancer.Vav3 oncogene is upregulated and a poor prognostic factor in breast cancer patientsAmerican Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerApproaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometryIn situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.Vascular measurements correlate with estrogen receptor statusPrognostic effect of preoperative serum estradiol level in postmenopausal breast cancerPrognostic and predictive value of low estrogen receptor expression in breast cancerMicroRNA regulation of progesterone receptor in breast cancerCentral pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancerBiopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives.RAS pathway biomarkers for breast cancer prognosis.Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER statusOverexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer.Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancerHyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Predictive value of pathological and immunohistochemical parameters for axillary lymph node metastasis in breast carcinoma.Oxidative stress-mediated apoptosis induced by ethanolic mango seed extract in cultured estrogen receptor positive breast cancer MCF-7 cells.Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancersInterpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negativeAssociation of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials.Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer studyQuality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approachThe Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma.
P2860
Q26743510-949971E5-EDB2-4A82-84D7-E7A72CDBB690Q26772870-7E72D28D-C52A-4AC1-81EA-CF68C1169037Q26830072-F0999489-302D-4D99-A9E8-7AB0863E64A6Q27316268-5E6E128D-D500-4C13-9AE9-1ADAE3C1BF78Q27851630-4A103242-3886-4AED-95D8-610C091FFE3CQ28074769-C9DF8A51-AD3E-47BD-B272-CA812FF8A9F4Q28393448-1A1109F4-D9D6-4185-8A15-F0011EC75BAFQ28730745-4B63FB13-3D14-4997-A430-FF09076E9849Q30240711-09013978-812F-46D7-A024-AD53ACC6CD58Q30384535-81CAF230-4C59-46D9-A112-C2AA7D70F0FAQ30494798-24DA7743-FDFF-4806-9FE6-7666696D17C4Q33418010-80909573-37B5-4514-A0E9-EF092395BAF4Q33468636-119AB6E8-8600-4B0A-B844-AFC5BEB4F553Q33561131-DDB1716F-5CA3-4E6E-970A-A2EC10B35EECQ33577008-6A2C5561-72EB-40C9-8D83-D87B0651572BQ33587216-894DD130-DE73-46BD-B749-1EF56718C771Q33611133-87DC6157-6ECA-4417-ADD9-DECED672DDE5Q33688484-09680484-F210-46E3-95FE-707B61351806Q33688726-76DE8194-053A-4119-8896-194AB88957B3Q33692020-89879E2A-BAE0-429B-AD86-E535272F0B37Q33721926-8EE6957E-49B5-4535-B7F6-C826C11444AFQ33738675-D0D962C2-06CB-4A14-8466-525E4F3F6674Q33757299-220D32B5-3F73-4EA6-BD51-179FF44E59C9Q33769803-184E0367-F3B8-4F60-9ED1-8354C72AF95AQ33804529-B6CFA3BE-1468-430B-A2DE-08E1B1715138Q33915010-14AADF7E-CFFD-4224-9439-96301BD0F60DQ33944557-AD7F140B-BD52-4EF5-849B-81A0F8AE9B1BQ33968076-FAB42894-68BA-451C-9541-EE26C226C74BQ34248282-AFD255B7-B0C4-4233-B636-938221AFE906Q34748822-EE701C83-A3C9-4DD4-8D95-5E823FCD6FE0Q35139094-B7CDAB1A-8AE1-4C3B-9188-299A281F7B2FQ35230273-EFE316A3-8E3F-44E0-8F83-3CE5E3FE0CE4Q35412323-B694D79E-1F63-49C8-85B1-B2687F3B5AB8Q35552416-6387B65C-E6ED-420D-B28D-0A6E509DF821Q35557992-54D2BB46-0758-44C3-B966-081458DD1757Q35584492-ED70B621-8D4B-45DF-87A6-DB90CA879273Q35611834-20E5E2FD-C60A-4516-A668-F868490C834BQ35690804-D6267BA5-1209-4F09-9208-7F6D5D075247Q35816286-A7C5E89B-BD63-4764-9AE5-876A0C8D0544Q35864395-2EEEF598-FB2E-4526-8A61-A0A3D40D369F
P2860
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Prognostic and predictive valu ...... early breast cancer: BIG 1-98.
@en
type
label
Prognostic and predictive valu ...... early breast cancer: BIG 1-98.
@en
prefLabel
Prognostic and predictive valu ...... early breast cancer: BIG 1-98.
@en
P2093
P356
P1476
Prognostic and predictive valu ...... early breast cancer: BIG 1-98.
@en
P2093
Alan S Coates
Aron Goldhirsch
Barry A Gusterson
Beat Thürlimann
Birgitte Bruun Rasmussen
Christian Ohlschlegel
Eugenio Maiorano
Johnny Raffoul
Karen N Price
Mauro G Mastropasqua
P304
P356
10.1200/JCO.2007.11.9453
P407
P577
2007-08-06T00:00:00Z